Omeros (OMER) Other Non-Current Assets (2010 - 2026)
Omeros recorded quarterly Other Non-Current Assets of $1.1 million in Q1 2026, little changed quarter-over-quarter from $1.1 million in Q4 2025, and little changed year-over-year from $1.1 million in Q1 2025.
Omeros' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (changed 0.0% YoY), while the FY2025 annual figure was $1.1 million, changed 0.0% from the prior year.
- Other Non-Current Assets came in at $1.1 million for Q1 2026 at Omeros, roughly flat from $1.1 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q1 2024 to a low of $1.1 million in Q1 2022.
- A 5-year average of $1.1 million and a median of $1.1 million in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 414.15% in 2022 and fell 4.18% in 2025, its largest moves.
- Omeros' Other Non-Current Assets stood at $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.1 million, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 1.05 Mn |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 1.05 Mn |
| Mar 31, 2022 | 1.05 Mn |
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 205,000.00 |
| Mar 31, 2021 | 1.05 Mn |
| Dec 31, 2020 | 1.06 Mn |
| Sep 30, 2020 | 1.15 Mn |
| Jun 30, 2020 | 1.15 Mn |
| Mar 31, 2020 | 1.01 Mn |
| Dec 31, 2019 | 1.15 Mn |
| Sep 30, 2019 | 1.15 Mn |
| Jun 30, 2019 | 1.16 Mn |
| Mar 31, 2019 | 1.15 Mn |
| Dec 31, 2018 | 1.15 Mn |
| Sep 30, 2018 | 5.78 Mn |
| Jun 30, 2018 | 5.78 Mn |
| Mar 31, 2018 | 5.84 Mn |
| Dec 31, 2017 | 5.84 Mn |
| Sep 30, 2017 | 5.84 Mn |
| Jun 30, 2017 | 5.84 Mn |
| Mar 31, 2017 | 5.84 Mn |
| Dec 31, 2016 | 5.84 Mn |
| Sep 30, 2016 | 10.84 Mn |
| Jun 30, 2016 | 10.68 Mn |
| Mar 31, 2016 | 10.68 Mn |
| Dec 31, 2015 | 219,000.00 |
| Sep 30, 2015 | 679,000.00 |
| Jun 30, 2015 | 679,000.00 |
| Mar 31, 2015 | 439,000.00 |
| Dec 31, 2014 | 679,000.00 |
| Sep 30, 2014 | 679,000.00 |
| Jun 30, 2014 | 439,000.00 |
| Mar 31, 2014 | 267,000.00 |
| Dec 31, 2013 | 100,000.00 |
| Sep 30, 2013 | 679,000.00 |
| Jun 30, 2013 | 679,000.00 |
| Mar 31, 2013 | 679,000.00 |
| Dec 31, 2012 | 679,000.00 |
| Sep 30, 2012 | 563,000.00 |
| Jun 30, 2012 | 235,000.00 |
| Mar 31, 2012 | 102,000.00 |
| Dec 31, 2011 | 193,000.00 |
| Sep 30, 2011 | 119,000.00 |
| Jun 30, 2011 | 136,000.00 |
| Dec 31, 2010 | 193,000.00 |